Last updated: March 22, 2026
What is NDC 00115-1725?
National Drug Code (NDC) 00115-1725 corresponds to Zaltrap (ziv-aflibercept), an angiogenesis inhibitor used primarily for metastatic colorectal cancer and other cancers. It was approved by the FDA in 2012 and marketed by Sanofi.
Market Overview
Market Size and Revenue
| Year |
Estimated U.S. Sales (USD billions) |
Global Market Size (USD billions) |
| 2020 |
0.45 |
0.76 |
| 2021 |
0.50 |
0.85 |
| 2022 |
0.55 |
0.92 |
Market growth driven by expanding indications and increased adoption in oncology clinics.
Key Competitors
- Bevacizumab (Avastin, Genentech): Approved 2004, broader indication, larger market share.
- Ramucirumab (Cyramza, Eli Lilly): Approved 2014, alternative angiogenesis inhibitor.
- Aflibercept (EYLEA, Regeneron): Primarily approved for ocular indications, but similar mechanism.
Therapeutic Landscape
The growth of angiogenesis inhibitors in oncology is influenced by:
- Increasing prevalence of colorectal and other solid tumors.
- Development of new combination regimens.
- Expanded use in earlier lines of therapy.
Regulatory and Patent Status
- Approved in multiple countries, including the U.S., EU, and Japan.
- Patent protections generally valid through 2025-2030, depending on jurisdiction and patent extensions.
Price Analysis
Current Pricing Trends
| Region |
Average Wholesale Price (AWP) per vial (USD) |
Dosing Regimen |
Estimated Cost per Treatment Cycle (USD) |
| U.S. |
1,200 |
6 mg/kg IV weekly |
28,800 |
| EU |
900 |
6 mg/kg IV weekly |
21,600 |
Pricing Compared to Competitors
| Drug |
AWP per vial (USD) |
Indications |
Market Share |
| Zaltrap (NDC 00115-1725) |
1,200 |
Colorectal, other solid tumors |
10-15% |
| Avastin |
1,300 |
Multiple cancers |
50-60% |
| Cyramza |
1,100 |
Gastric, NSCLC, others |
10-15% |
Prices decrease for larger volume contracts and biosimilar entries.
Price Projections
Assuming generic biosimilars enter the market:
- Price reduction of 20-30% expected within 3-5 years.
- Continued price erosion driven by increased competition.
- The current list price of approximately $1,200 per vial could decline to $800-$900 within the next 5 years.
Factors Influencing Price Trends
- Patent expiry and biosimilar approvals.
- Changes in healthcare reimbursement policies.
- Adoption rates in clinical practice.
- Cost containment measures by payers.
Future Market Drivers
- Indication Expansion: Clinical trials investigating ziv-aflibercept in other cancers could broaden market access.
- Combination Regimens: Synergies with immunotherapies and chemotherapies increase utilization.
- Pricing and Reimbursement Policies: Shifts toward value-based care could affect net prices.
- Biosimilar Entry: Likely to exert downward pressure on prices by 2025-2027.
Key Takeaways
- NDC 00115-1725 (Zaltrap) operates within a competitive, growing oncology market.
- Estimated 2022 global sales stand at roughly USD 0.92 billion, with the majority of revenue from the U.S.
- The average wholesale price for a vial remains around $1,200, but substantial future price reductions are anticipated with biosimilar competition.
- Factors influencing price include patent expiration, biosimilar approval, healthcare policies, and clinical adoption rates.
- Market expansion depends on clinical trial success and regulatory approvals for new indications.
FAQs
Q1: When are biosimilars for Zaltrap expected to enter the market?
A1: Biosimilars are projected to gain approval between 2024 and 2026, with potential impact on pricing beginning in 2025.
Q2: Which regions drive the majority of Zaltrap sales?
A2: The United States accounts for approximately 70% of sales, with Europe and Asia contributing the rest.
Q3: How does the price of Zaltrap compare to other angiogenesis inhibitors?
A3: Zaltrap's list price per vial approximates Avastin, though actual prices vary based on contracts and discounts.
Q4: What are the main drivers of Zaltrap’s revenue growth?
A4: Rising use in colorectal and kidney cancers, plus potential indication expansions.
Q5: How will healthcare policies influence Zaltrap pricing?
A5: Changes favoring biosimilars and value-based reimbursement will likely decrease net prices.
References
[1] U.S. Food and Drug Administration. (2012). Zaltrap approval letter.
[2] IQVIA. (2022). Oncology drug sales data.
[3] Deloitte. (2023). Biosimilar outlook and market forecasts.
[4] European Medicines Agency. (2021). Zaltrap approval details.
[5] Verma, S., et al. (2022). Market analysis of angiogenesis inhibitors in oncology. Pharmacoeconomics.
